Report ID: SQMIG35J2060
Report ID:
SQMIG35J2060 |
Region:
Global |
Published Date: August, 2024
Pages:
219
|
Tables:
61 |
Figures:
75
Global Liquid Biopsy Market was valued at around USD 9.28 Billion in 2022 and is expected to rise from USD 10.32 Billion in 2023 to reach a value of USD 24.14 Billion by 2031, at a CAGR of 11.21% during the forecast period (2024–2031).
Global liquid biopsy market is growing rapidly due to its non-invasive nature and increasing incidence of cancer worldwide. Liquid biopsy offers a non-invasive alternative and offers, traditional histology allows for faster cancer diagnosis, monitoring and personalized therapy. Next generation sequencing (NGS) and polymer chain reaction (PCR) have dramatically increased the sensitivity and specificity of liquid biopsies, driving the market growth. Furthermore, the need for full validation and standardization of urine samples is an important limitation. Despite these challenges, the market is poised for significant growth, driven by ongoing R&D activities and increasing focus on personalized medicine. Some AI and ML algorithms are available that can analyze large data sets from liquid biopsy tests to identify the patterns and biomarkers associated with cancer, enabling identification and accurate and timely treatment.
Our industry expert will work with you to provide you with customized data in a short amount of time.
REQUEST FREE CUSTOMIZATIONWant to customize this report? This report can be personalized according to your needs. Our analysts and industry experts will work directly with you to understand your requirements and provide you with customized data in a short amount of time. We offer $1000 worth of FREE customization at the time of purchase.
Report ID: SQMIG35J2060